In line with the clinical data, NET treatment in vitro impaired the cytotoxic efficacy of anthracycline drugs, which was efficiently reduced by CCDC25 knockout in HR+ breast cancer cells, including MCF-7 cells and T47D cells (Figure 6H and Supplemental Figure 10, E–H). Here, CCDC25 is linked to breast carcinoma.